ACRV · ISSUER CIK 1781174
Acrivon Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 7 Acrivon Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $40K of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 9 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$40KInsider selling
−$40KNet open-market
Oct 26, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 202616:03 | Oct 22, 2026 | ACRV | Chief Legal Officer | S · Sell | $1.84 | −513 | 81,202 | -1% | −$943.92 | ||
| Oct 7, 202617:02 | Oct 5, 2026 | ACRV | Chief Legal Officer | S · Sell | $1.99 | −294 | 81,715 | -0% | −$585.06 | ||
| Sep 2, 202616:30 | Aug 31, 2026 | ACRV | Chief Business Officer | A · Grant | — | +30,000 | 30,000 | New | — | ||
| Aug 27, 202616:14 | Aug 25, 2026 | ACRV | President and CEO, Director · +1 joint | S · Sell | $2.21 | −14,036 | 2,230,052 | -1% | −$31K | ||
| Aug 20, 202616:10 | Aug 18, 2026 | ACRV | Chief Accounting Officer | S · Sell | $2.01 | −101 | 18,033 | -1% | −$203.01 | ||
| Aug 20, 202616:09 | Aug 18, 2026 | ACRV | Chief Legal Officer | S · Sell | $2.01 | −185 | 82,009 | -0% | −$371.85 | ||
| Aug 20, 202616:08 | Aug 18, 2026 | ACRV | Chief Development Officer | S · Sell | $2.01 | −400 | 52,592 | -1% | −$804.00 | ||
| Aug 20, 202616:07 | Aug 18, 2026 | ACRV | Chief Operating Officer | S · Sell | $2.01 | −604 | 146,349 | -0% | −$1K | ||
| Aug 20, 202616:07 | Aug 18, 2026 | ACRV | President and CEO, Director · +1 joint | S · Sell | $2.01 | −1,713 | 2,244,088 | -0% | −$3K | ||
| Aug 6, 202616:34 | Aug 4, 2026 | ACRV | Chief Financial Officer | S · Sell | $1.57 | −1,142 | 66,008 | -2% | −$2K |